Compare Eli Lilly And Co (LLY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Wells Fargo & Co — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Eli Lilly And Co is far larger — about 4.2× Wells Fargo & Co's market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Wells Fargo & Co for 88 Days on average.
| LLY | WFC | |
|---|---|---|
Market Cap | $1.04T | $248.06B |
Volume | 3,064,878 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $1.28K | $96.40 |
52-Week Low | $799.57 | $73.42 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $1.09T | $503.91B |
Dividend Yield | 0.59% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Wells Fargo (WFC) trades at $82.06, up 2.24% on the day, with a bearish technical signal from moving averages. The stock's valuation appears attractive with a P/E of 11.92 and P/B of 1.5, while profitability remains strong with a 25.97% net income margin. Recent news includes a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and upcoming Q3 earnings on October 13, 2026 (Benzinga, 2026-09-29).
The outlook is mixed: analyst consensus targets $99.13 (46.66% buy ratings), but recent earnings misses and a negative cash flow trend in 2025 pose risks. Upside potential hinges on execution amid Fed policy changes and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
